Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study.

Daud ANA, Bergman JEH, Kerstjens-Frederikse WS, van der Vlies P, Hak E, Berger RMF, Groen H, Wilffert B.

Pharmacogenomics. 2017 Jul;18(10):987-1001. doi: 10.2217/pgs-2017-0036. Epub 2017 Jun 22.

2.

Knowledge and attitude regarding pharmacogenetics among formerly pregnant women in the Netherlands and their interest in pharmacogenetic research.

Daud ANA, Bergsma EL, Bergman JEH, De Walle HEK, Kerstjens-Frederikse WS, Bijker BJ, Hak E, Wilffert B.

BMC Pregnancy Childbirth. 2017 Apr 14;17(1):120. doi: 10.1186/s12884-017-1290-z.

3.

Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies.

Daud AN, Bergman JE, Oktora MP, Kerstjens-Frederikse WS, Groen H, Bos JH, Hak E, Wilffert B.

PLoS One. 2017 Mar 13;12(3):e0173530. doi: 10.1371/journal.pone.0173530. eCollection 2017.

4.

The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?

Daud AN, Bergman JE, Kerstjens-Frederikse WS, Groen H, Wilffert B.

Int J Mol Sci. 2016 Aug 13;17(8). pii: E1333. doi: 10.3390/ijms17081333. Review.

5.

P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study.

Daud AN, Bergman JE, Bakker MK, Wang H, Kerstjens-Frederikse WS, de Walle HE, Groen H, Bos JH, Hak E, Wilffert B.

Drug Saf. 2015 Jul;38(7):651-9. doi: 10.1007/s40264-015-0299-3.

6.

Pharmacogenetics of drug-induced birth defects: the role of polymorphisms of placental transporter proteins.

Daud AN, Bergman JE, Bakker MK, Wang H, de Walle HE, Plösch T, Wilffert B.

Pharmacogenomics. 2014 May;15(7):1029-41. doi: 10.2217/pgs.14.62. Review.

PMID:
24956255
7.

Prostaglandin E2 mediates growth arrest in NFS-60 cells by down-regulating interleukin-6 receptor expression.

de Silva KI, Daud AN, Deng J, Jones SB, Gamelli RL, Shankar R.

Biochem J. 2003 Feb 15;370(Pt 1):315-21.

8.

Block of cloned human T-type calcium channels by succinimide antiepileptic drugs.

Gomora JC, Daud AN, Weiergräber M, Perez-Reyes E.

Mol Pharmacol. 2001 Nov;60(5):1121-32.

PMID:
11641441
9.

Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications.

Daud AN, Ahsan A, Iqbal O, Walenga JM, Silver PJ, Ahmad S, Fareed J.

Clin Appl Thromb Hemost. 2001 Jan;7(1):58-64.

PMID:
11190907
10.

Anticoagulant and antiprotease effects of a novel heparinlike compound from shrimp (Penaeus brasiliensis) and its neutralization by heparinase I.

Demir M, Iqbal O, Dietrich CP, Hoppensteadt DA, Ahmad S, Daud AN, Fareed J.

Clin Appl Thromb Hemost. 2001 Jan;7(1):44-52.

PMID:
11190904
11.

Corrigendum to: molecular cloning and functional expression of ca(v)3.1c, a T-type calcium channel from human brain.

Cribbs LL, Gomora JC, Daud AN, Lee J, Perez-Reyes E.

FEBS Lett. 2000 Mar 31;470(3):378. No abstract available.

12.

Molecular cloning and functional expression of Ca(v)3.1c, a T-type calcium channel from human brain.

Cribbs LL, Gomora JC, Daud AN, Lee JH, Perez-Reyes E.

FEBS Lett. 2000 Jan 21;466(1):54-8. Erratum in: FEBS Lett 2000 Mar 31;470(3):378.

13.

Cloning and expression of a novel member of the low voltage-activated T-type calcium channel family.

Lee JH, Daud AN, Cribbs LL, Lacerda AE, Pereverzev A, Klöckner U, Schneider T, Perez-Reyes E.

J Neurosci. 1999 Mar 15;19(6):1912-21.

Supplemental Content

Support Center